Second Prize of Chinese Medical Science and Technology Award,
Second Prize of the Ministry of Education Science and Technology Progress Award,
Second Prize of Beijing Municipal Science and Technology Progress Award
Led national key scientific and technological programs under the 10th, 11th, and 12th Five-Year Plans. Developed optimized treatment protocols for chronic hepatitis C, which have been incorporated into the WHO Guidelines, the APASL Guidelines, and China’s Guidelines for the Prevention and Treatment of Chronic Hepatitis C. Established the industry standard Screening and Management of Hepatitis C based on the epidemiological features in China, which is recommended in the National Action Plan for Eliminating the Public Health Threat of Hepatitis C (2021–2030) issued by the National Health Commission and nine other ministries. Currently leading a national key R&D program to develop a non-staining, fully automated, AI-powered, quantitative system for multi-dimensional assessment of liver histology in NAFLD, which has been adopted by the AASLD Guidelines on NAFLD and used by multiple multinational pharmaceutical companies for drug efficacy evaluation. Also led a sub-project under the 973 Program on redefining the threshold for hepatitis B surface antigen seroclearance, which has been incorporated into the EASL Guidelines on Hepatitis B. These research results have been published in Gastroenterology, Lancet Gastroenterology and Hepatology, and Hepatology.
